35808-68-5

Basic information

• Product Name: 4-Chloro-6-methyl-7H-pyrrolo[2,3-d]pyrimidine
• Synonyms: 4-Chloro-6-methyl-7H-pyrrolo[2,3-d]pyrimidine;4-Chloro-6-Methyl-7H-pyrr...;4-chloro-6-methyl-1H-pyrrolo[2,3-d]pyrimidine;NSC 344519;1H-Pyrrolo[2,3-d]pyrimidine, 4-chloro-6-methyl-
• CAS NO: 35808-68-5
• Molecular Formula: C₇H₆ClN₃
• Molecular Weight: 167.598
• EINECS: 205-525-8
• Product Categories: Heterocycle-Pyrimidine series
• Mol File: 35808-68-5.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 329.2 °C at 760 mmHg
• Flash Point: 182.9 °C
• Appearance: /
• Density: 1.438 g/cm³
• Vapor Pressure: 0.000345mmHg at 25°C
• Refractive Index: 1.687
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 11.49±0.40(Predicted)
• CAS DataBase Reference: 4-Chloro-6-methyl-7H-pyrrolo[2,3-d]pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Chloro-6-methyl-7H-pyrrolo[2,3-d]pyrimidine(35808-68-5)
• EPA Substance Registry System: 4-Chloro-6-methyl-7H-pyrrolo[2,3-d]pyrimidine(35808-68-5)

Safety Data

• Hazardous Substances Data: 35808-68-5(Hazardous Substances Data)

Usage

General Description

4-Chloro-6-methyl-7H-pyrrolo[2,3-d]pyrimidine is a chemical compound with the molecular formula C7H6ClN3. This heterocyclic compound consists of a pyrrolopyrimidine core with a chlorine atom at the 4-position and a methyl group at the 6-position. It is a white to off-white crystalline solid that is used in the synthesis of pharmaceuticals and other organic compounds. Its structure and properties make it a valuable building block in drug discovery and development, particularly in the field of medicinal chemistry. 4-Chloro-6-methyl-7H-pyrrolo[2,3-d]pyrimidine has potential applications in the development of new therapeutic agents for a variety of medical conditions.

InChI:InChI=1/C7H6ClN3/c1-4-2-5-6(8)9-3-10-7(5)11-4/h2-3H,1H3,(H,9,10,11)

Upstream product

• 252723-16-3 4-chloro-6-methyl-7-(phenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidine 

Downstream Products

• 1613479-17-6 C₁₃H₉F₂N₃O 
• 1229936-89-3 (2R,3S,5R)-5-(4-amino-6-methyl-5-(2-(2-methyl-5-phenylthiophen-3-yl)cyclopent-1-en-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-(hydroxymethyl)tetrahydrofuran-3-ol 
• 1219727-45-3 N-isopropyl-3-(3-(4-(6-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)ureido)benzamide 
• 1414357-44-0 (S)-tert-butyl 2-((4-chloro-6-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl)pyrrolidine-1-carboxylate 
• 1229936-44-0 4-chloro-5-iodo-6-methyl-7H-pyrrolo[2,3-d]pyrimidine 
• 35808-69-6 4-chloro-6,7-dimethyl-7H-pyrrolo[2,3-d]pyrimidine 

Relevant articles and documents

ATROPISOMERISM FOR ENHANCED KINASE INHIBITOR SELECTIVITY

The invention provides a series of conformationally stable and selective kinase inhibitors, and methods of using the kinase inhibitors. The effect of atropisomerism on kinase selectivity was assessed, finding improved selectivity compared to rapidly inter

TREATMENT OF DRY EYE

The present disclosure provides a method of treating dry eye by inhibition of Bruton's tyrosine kinase (hereinafter "BTK") inhibitors, pharmaceutical formulations comprising the same, and processes for preparing such compounds.

PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS

The present invention relates to 6-amino-7-deaza-purine derivatives which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity, in particular RET family kinases. The present